Background/Aim: Cabazitaxel use has usually been limited to up to 10 cycles in most
countries according to the protocol in the TROPIC trial. Therefore, clinical data on …

Objective This study aimed to reveal the efficacy and safety profiles of 4-weekly cabazitaxel
in patients with castration-resistant prostate cancer (CRPC). Methods The study included 62 …

Background/Aim: Cabazitaxel (CBZ) is approved for docetaxel-resistant castration-resistant
prostate cancer (CRPC). This retrospective study aimed at assessing the efficacy and …

This multi-institutional study aimed to investigate the efficacy and safety profiles of
cabazitaxel after prior docetaxel chemotherapy in patients with castration-resistant prostate …

Prostate cancer is the most common malignancy in male patients. The second‐generation
taxanes, cabazitaxel, is a therapeutic option with an overall survival advantage for patients …

Objectives Cabazitaxel is a next‐generation taxane that can prolong overall survival after
docetaxel treatment in patients with metastatic castration‐resistant prostate cancer …

Background The recommended starting dose of cabazitaxel for castration-resistant prostate
cancer (CRPC) is 25 mg/m 2 in Japan and Europe. Although lower doses are established …

Background Several studies have reported the efficacy of cabazitaxel in cancer therapy;
however, investigations of its safety are few. The aim of this study was to retrospectively …

We examined factors that may impact cabazitaxel treatment duration in a real-life setting in a
compassionate use program, expanded access program, and prospective observational …

Background The correlation of the oncological outcomes of docetaxel and cabazitaxel in
Japanese metastatic castration-resistant prostate cancer (mCRPC) patients has not been …